Clinical features and treatment outcomes of necrotizing autoimmune myopathy

JAMA Neurology

Volumn 72, Issue 9, 2015, Pages 996-1003

  Kassardjian, Charles D ^a   Lennon, Vanda A ^a,b   Alfugham, Nora B ^a   Mahler, Michael ^c   Milone, Margherita ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c INOVA DIAGNOSTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PRAVASTATIN; PREDNISONE; ROSUVASTATIN; SIMVASTATIN; CORTICOTROPIN RELEASING FACTOR; HMGCR PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IMMUNOGLOBULIN G; UCN2 PROTEIN, HUMAN; UROCORTIN;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DYSPHAGIA; DYSPNEA; FEMALE; GASTROINTESTINAL CARCINOMA; HEART PALPITATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NECROTIZING AUTOIMMUNE MYOPATHY; OVARY ADENOCARCINOMA; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; SEROLOGY; THORAX PAIN; THYMOMA; TREATMENT OUTCOME; WEIGHT REDUCTION; AUTOIMMUNE DISEASES; BLOOD; COMPLICATION; ELECTROMYOGRAPHY; EVOKED MUSCLE RESPONSE; FOLLOW UP; HEART DISEASES; IMMUNOLOGY; IMMUNOTHERAPY; LUNG DISEASES; MIDDLE AGED; MUSCULAR DISEASES; NECROSIS; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SKELETAL MUSCLE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; CORTICOTROPIN-RELEASING HORMONE; ELECTROMYOGRAPHY; EVOKED POTENTIALS, MOTOR; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; IMMUNOGLOBULIN G; IMMUNOTHERAPY; LUNG DISEASES; MALE; MIDDLE AGED; MUSCLE FIBERS, SKELETAL; MUSCULAR DISEASES; NECROSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UROCORTINS;

EID: 84942238174     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.1207     Document Type: Article

References (39)

1. Liang C, Needham M. Necrotizing autoimmune myopathy. Curr Opin Rheumatol. 2011;23(6):612-619.
2. Luo YB, Mastaglia FL. Dermatomyositis, polymyositis and immune-mediated necrotising myopathies. Biochim Biophys Acta. 2015;1852(4):622-632.
3. De Bleecker JL, De Paepe B, Aronica E, et al; ENMC Myositis Muscle Biopsy Study Group. 205th ENMC International Workshop: pathology diagnosis of idiopathic inflammatory myopathies part II 28-30 March 2014, Naarden, The Netherlands. Neuromuscul Disord. 2015;25(3):268-272.
4. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC International Workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14(5):337-345.
5. Pestronk A. Acquired immune and inflammatory myopathies: pathologic classification. Curr Opin Rheumatol. 2011;23(6):595-604.
6. Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve. 2010;41(2):185-190.
7. Allenbach Y, Drouot L, Rigolet A, et al; French Myositis Network. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore). 2014;93(3):150-157.
8. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713-721.
9. Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord. 2007;17(2):194-200.
10. Emslie-Smith AM, Engel AG. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology. 1991;41(6):936-939.
11. Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A. Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology. 1998;50(3):764-767.
12. Wrzolek MA, Sher JH, Kozlowski PB, Rao C. Skeletal muscle pathology in AIDS: an autopsy study. Muscle Nerve. 1990;13(6):508-515.
13. Mohassel P, Mammen AL. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. Muscle Nerve. 2013;48(4):477-483.
14. Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry. 2002;73(4):420-428.
15. Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum. 1990;33(9):1361-1370.
16. Scripko PD, Amato AA, Puig A. Mystery case: a 63-year-old man with progressive proximal pain and weakness. Neurology. 2014;82(4):e26-e29.
17. Bronner IM, Hoogendijk JE, Wintzen AR, et al. Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol. 2003;250(4):480-485.
18. Ellis E, Ann Tan J, Lester S, et al. Necrotizing myopathy: clinicoserologic associations. Muscle Nerve. 2012;45(2):189-194.
19. van de Vlekkert J, Hoogendijk JE, de Visser M. Long-term follow-up of 62 patients with myositis. J Neurol. 2014;261(5):992-998.
20. Bronner IM, van der Meulen MF, de Visser M, et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis. 2006;65(11):1456-1461.
21. Fernandez C, Bardin N, De Paula AM, et al. Correlation of clinicoserologic and pathologic classifications of inflammatory myopathies: study of 178 cases and guidelines for diagnosis. Medicine (Baltimore). 2013;92(1):15-24.
22. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62(9):2757-2766.
23. Apiwattanakul M, Milone M, Kryzer TJ, et al. Signal recognition particle subunit-specific immunoglobulin G (54 and 72) biomarkers for autoimmune necrotizing or inflammatory myopathy and neoplasia [abstract]. Muscle Nerve. 2011;44(4):623-694.
24. Musset L, Miyara M, Benveniste O, et al. Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies. J Immunol Res. 2014;2014:405956.
25. Benveniste O, Drouot L, Jouen F, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum. 2011;63(7):1961-1971.
26. Suzuki S, Hayashi YK, Kuwana M, Tsuburaya R, Suzuki N, Nishino I. Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome. Arch Neurol. 2012;69(6):728-732.
27. Chung T, Christopher-Stine L, Paik JJ, Corse A, Mammen AL. The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy [published online March 3, 2015]. Muscle Nerve. doi:10.1002/mus.24642.
28. Wegener S, Bremer J, Komminoth P, Jung HH, Weller M. Paraneoplastic necrotizing myopathy with a mild inflammatory component: a case report and review of the literature. Case Rep Oncol. 2010;3(1):88-92.
29. Suzuki S, Yonekawa T, Kuwana M, et al. Clinical and histological findings associated with autoantibodies detected by RNA immunoprecipitation in inflammatory myopathies. J Neuroimmunol. 2014;274(1-2):202-208.
30. Brouwer R, Hengstman GJ, Vree Egberts W, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis. 2001;60(2):116-123.
31. Hengstman GJ, ter Laak HJ, Vree Egberts WT, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis. 2006;65(12):1635-1638.
32. Jaffe AS, Vasile VC,Milone M, Saenger AK, Olson KN, Apple FS. Diseased skeletal muscle: a noncardiac source of increased circulating concentrations of cardiac troponin T. J Am Coll Cardiol. 2011;58(17):1819-1824.
33. Mavrogeni S, Sfikakis PP, Dimitroulas T, Kolovou G, Kitas GD. Cardiac and muscular involvement in idiopathic inflammatory myopathies: noninvasive diagnostic assessment and the role of cardiovascular and skeletal magnetic resonance imaging. Inflamm Allergy Drug Targets. 2014;13(3):206-216.
34. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991;70(6):360-374.
35. Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken). 2010;62(9):1328-1334.
36. Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum. 2004;50(1):209-215.
37. Garcia-Rosell M, Moore S, Pattanaik D, Menon Y, Bertorini T, Carbone L. Signal recognition antibody-positive myopathy and response to intravenous immunoglobulin G (IVIG). J Clin Rheumatol. 2013;19(4):214-217.
38. Meriggioli MN, Barboi AC, Rowin J, Cochran EJ. HMG-CoA reductase inhibitor myopathy: clinical, electrophysiological, and pathologic data in five patients. J Clin Neuromuscul Dis. 2001;2(3):129-134.
39. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B Met. 1995;57(1):289-300.